Olaparib and SOLO2 Trial: 52% of Patients Had a Partial Response - 102134

Spotlight
Video

Olaparib and SOLO2 Trial: 52% of Patients Had a Partial Response

SGO2017 has 36 videos Subscribe Here

Loading........
Description: Don Dizon, MD of Massachusetts General Hospital gives an overview of the SOLO2 Trial and the use of olaparib in ovarian cancer. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)’s Annual Meeting on Women’s Cancer® in National Harbor, MD.
Shared By : SGO2017
Posted on : 03/21/17
Added : 11 months ago
Category : Ovarian Cancer



Recommended

Nothing found.

More From SGO2017

Nothing found.